Publications:

Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.

Biomedicines

Bai, Zhengli Z; Xu, Menglong M; Mei, Ying Y; Hu, Tuo T; Zhang, Panpan P; Chen, Manman M; Lv, Wenxiu W; Lu, Chenchen C; Tan, Shuhua S

Publication Date: 2021-11-27

Variant appearance in text: LDLR: N297G

PubMed Link: 34944600

Variant Present in the following documents:

• Main text
• biomedicines-09-01783.pdf

View BVdb publication page

Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.

Biomedicines

Bai, Zhengli Z; Xu, Menglong M; Mei, Ying Y; Hu, Tuo T; Zhang, Panpan P; Chen, Manman M; Lv, Wenxiu W; Lu, Chenchen C; Tan, Shuhua S

Publication Date: 2021-11-27

Variant appearance in text: LDLR: N297G

PubMed Link: 34944600

Variant Present in the following documents:

• Main text
• biomedicines-09-01783.pdf

View BVdb publication page

Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.

Ebiomedicine

Xu, Menglong M; Lei, Gaoxin G; Chen, Manman M; Wang, Ke K; Lv, Wenxiu W; Zhang, Panpan P; Hu, Tuo T; Gao, Jie J; Lu, Chenchen C; Mei, Ying Y; Xu, Zhipan Z; Bai, Zhengli Z; Hu, Huajing H; Jiang, Yiwei Y; Tan, Shuhua S

Publication Date: 2021-03

Variant appearance in text: LDLR: N297G

PubMed Link: 33647772

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page